Does Humira Raise Liver Enzymes?
Humira (adalimumab), a TNF inhibitor for autoimmune conditions like rheumatoid arthritis and Crohn's disease, can increase liver enzymes in some patients. Clinical trials and post-marketing data show elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, typically mild and reversible upon discontinuation. In rheumatoid arthritis studies, about 4% of patients had ALT elevations >3 times the upper limit of normal (ULN), compared to 1% on placebo.[1][2]
Hepatotoxicity is listed in Humira's prescribing information as a potential adverse reaction, with monitoring recommended before and during treatment, especially in patients with liver disease or risk factors like alcohol use.[3]
How Common Are Elevated Liver Enzymes on Humira?
Incidence varies by indication:
- Rheumatoid arthritis: ALT >3x ULN in 3-4% of patients; AST similarly low.[1]
- Psoriatic arthritis: Around 2-5%.[2]
- Ulcerative colitis: Up to 5-7% in trials.[4]
Most cases resolve without intervention, but severe elevations (>5x ULN) occur in <1% and may signal drug-induced liver injury (DILI).[5]
Why Does Humira Affect the Liver?
Humira suppresses TNF-alpha, which plays a role in liver inflammation. Paradoxically, this can lead to transient enzyme spikes, often within the first 6 months. Risk factors include:
- Concomitant hepatotoxic drugs (e.g., methotrexate).
- Pre-existing liver conditions like fatty liver or hepatitis.
- Infections, as Humira increases reactivation risk (e.g., hepatitis B).[3][6]
No direct causal mechanism is fully proven, but it's a class effect among anti-TNF biologics.
What Should Patients Do If Enzymes Rise?
Doctors typically:
- Check baseline liver function tests (LFTs).
- Monitor every 1-3 months initially.
- Dose-hold or stop if >3x ULN persists.[3]
Patients report fatigue or jaundice rarely; most notice no symptoms. Consult a doctor before starting—do not self-adjust.
How Does Humira Compare to Other Biologics for Liver Risk?
| Drug | ALT >3x ULN Incidence | Notes |
|------|-----------------------|------|
| Humira | 3-7% | Common but mild[1] |
| Enbrel (etanercept) | 2-4% | Similar profile[7] |
| Stelara (ustekinumab) | <2% | Lower risk, IL-12/23 inhibitor[8] |
| Methotrexate (non-biologic) | 5-15% | Higher, often combo with Humira[9] |
Humira's risk is average for TNF blockers but higher than non-TNF biologics.
Who Is at Higher Risk and When to Avoid?
Avoid or use caution in:
- Active hepatitis B/C carriers (screen first).[3]
- Heavy drinkers.
- Those with cirrhosis.
Pregnant patients: Limited data, but enzymes monitored closely.[10]
[1]: Humira Prescribing Information (FDA)
[2]: Rheumatoid Arthritis Clinical Trials Data (AbbVie)
[3]: Humira Label - Hepatic Warnings
[4]: UC Trial Results (NEJM, 2012)
[5]: LiverTox Database - Adalimumab (NIH)
[6]: EASL Guidelines on DILI
[7]: Enbrel Label (FDA)
[8]: Stelara Label (FDA)
[9]: Methotrexate Hepatotoxicity Review (Arthritis Rheum)
[10]: Humira Pregnancy Registry Data (MotherToBaby)